Inicio › Mieloma múltiple › Texas

Ensayos clínicos de Mieloma múltiple en Texas

53 estudios sobre Mieloma múltiple buscan participantes en Texas.

Ciudades en Texas

Texto oficial del estudio (inglés)

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site, Austin
Research Site, Dallas
Research Site, Houston

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

MD Anderson Cancer Center, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05652335

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

MD Anderson, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07336472

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

MD Anderson Cancer Center, Houston

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05201781

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

St. David's South Austin Medical Center, Austin
Baylor University Medical Center, Dallas
UT Southwestern Medical Center, Dallas
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07258511

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

University of Texas Southwestern Medical Center, Dallas
Houston Methodist Hospital, Houston
Joe Arrington Cancer Research Treatment Center, Lubbock

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05552222

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Research Site, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07073547

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Baylor University Medical Center, Dallas
Joe Arrington Cancer Research Treatment Center, Lubbock

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

The University of Texas MD Anderson Cancer Center, Houston

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05623020

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Oncology Consultants (P1 Trials -Exigent Network), Houston
Lumi Research, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT07477587

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The University of Texas MD Anderson Cancer Center, Houston

ReclutandoFase 2

Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Texas Oncology - The Woodlands /ID# 278726, The Woodlands
Texas Oncology - Northeast Texas /ID# 278725, Tyler

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07095452

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

The University of Texas MD Anderson Cancer Center, Houston

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07648264

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

MD Anderson Cancer Center, Houston

ReclutandoFase 2

Todas las edades · Todos los sexos · Actualizado el 18 sept 2026 · NCT07382739

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

MD Anderson Cancer Center, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT04879043

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

University of Texas MD Anderson Cancer Center, Houston

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06615479

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Texas - Southwestern Medical Center /ID# 271914, Dallas

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06953960

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

UT Southwestern Medical Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute, San Antonio

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06297226

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Texas MD Anderson Cancer Center, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06988488

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 ago 2026 · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
Baylor University Medical Center, Dallas
Houston Methodist Cancer Center Infusion, Houston
y 9 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06152575

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

GSK Investigational Site, Fort Worth

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT05714839

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

MD Anderson Cancer Center, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06292780

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site, Austin
Research Site, Dallas
Research Site, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05850234

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

MD Anderson Cancer Center, Houston

ReclutandoFase 2Se aceptan voluntarios sanos

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT05091372

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, Dallas
Research Site, Houston

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Baylor University Medical Center, Dallas
Houston Methodist Hospital, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT07280013

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

M D Anderson Cancer Center, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 ago 2026 · NCT06105554

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

MD Anderson Cancer Center, Houston

ReclutandoFase 2

Edades de 18 a 75 · Todos los sexos · Actualizado el 10 ago 2026 · NCT06207799

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M D Anderson Cancer Center, Houston

ReclutandoFase 1/2

Edades de 12 a 80 · Todos los sexos · Actualizado el 7 ago 2026 · NCT05092451

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

START San Antonio, San Antonio

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT07284758

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

University of Texas - Southwestern Medical Center /ID# 274360, Dallas

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 jul 2026 · NCT06892522

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Texas MD Anderson Cancer Center, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 jul 2026 · NCT06121843

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Texas Oncology - Central/South Texas /ID# 268563, Austin
Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
Oncology Consultants /ID# 268323, Houston
y 1 más

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT05650632

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

University of Texas Southwestern, Dallas

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 jul 2026 · NCT05137054

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

St. David's South Austin Medical Center, Austin

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 jul 2026 · NCT06057402

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

MD Anderson in The Woodlands, Conroe
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Ben Taub General Hospital, Houston
y 6 más

ReclutandoFase 3

Todas las edades · Todos los sexos · Actualizado el 10 jun 2026 · NCT05561387

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

M D Anderson Cancer Center, Houston

ReclutandoFase 2

Edades de 18 a 72 · Todos los sexos · Actualizado el 8 jun 2026 · NCT05776979

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

University of Texas Southwestern, Dallas

ReclutandoFase 2

Edades de 19 en adelante · Todos los sexos · Actualizado el 4 jun 2026 · NCT06974786

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.